STOCK TITAN

Ensysce Biosciences Inc Stock Price, News & Analysis

ENSCW Nasdaq

Welcome to our dedicated page for Ensysce Biosciences news (Ticker: enscw), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences stock.

Ensysce Biosciences Inc. (ENSCW) is a clinical-stage biopharmaceutical innovator developing abuse-deterrent opioid therapies using its proprietary TAAP and MPAR platforms. This page provides timely updates on the company’s advancements in pain management and opioid use disorder treatment.

Investors and stakeholders will find verified news on clinical trial milestones, regulatory developments, and strategic collaborations. Key updates include progress on PF614 (TAAP-activated pain therapy), PF614-MPAR (overdose-resistant candidate), and FDA-designated programs.

This resource consolidates press releases covering financial results, intellectual property expansions, and manufacturing partnerships. Bookmark this page to track Ensysce’s progress in addressing critical public health challenges through safer prescription drug technologies.

Rhea-AI Summary

Ensysce Biosciences, a clinical-stage biotech firm, reported Q3 2022 financials highlighting a net loss of $9.9 million, a decrease from $17.2 million year-over-year. Cash reserves stood at $4.5 million, up from $3.7 million in the previous quarter. The CEO noted positive topline results from the human abuse potential study of PF614, indicating its advantages over existing products. Furthermore, the FDA provided guidance supporting PF614's development for acute pain. R&D expenses surged to $4.8 million, reflecting ongoing clinical activities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Ensysce Biosciences (NASDAQ:ENSC) announced receiving FDA guidance regarding its lead product, PF614, indicating that pursuing an acute pain indication is advisable. The FDA's non-binding guidance suggests conducting two clinical trials comparing PF614 with a placebo and an immediate-release opioid like oxycodone. This strategy may reduce the development timeline and costs, compared to a chronic pain focus. Ensysce plans to advance PF614 for acute pain while continuing chronic pain development, aiming to complete human abuse potential studies and initiate Phase 3 trials in the upcoming year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Ensysce Biosciences has announced positive topline results from a human abuse potential (HAP) study of PF614, an innovative oxycodone product designed to deter abuse. The study demonstrated that PF614 resulted in significantly lower peak 'drug liking' compared to traditional oxycodone. This is crucial for its FDA approval process, aligning with the agency's guidance on evaluating abuse potential. The company is committed to advancing this product into Phase 3 studies, addressing a significant need for safer analgesics in chronic pain management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Ensysce Biosciences (NASDAQ:ENSC) has initiated the PF614-104 study, focusing on the drug's abuse deterrent properties against oxycodone. The trial tests the oral abuse potential of PF614 in non-dependent recreational opioid users, comparing it to oxycodone and placebo. The study's primary outcome is 'Drug Liking,' essential for future commercialization and labeling. Ensysce's TAAP® technology ensures PF614 is inert without trypsin exposure, potentially reducing abuse risks. Preliminary data is expected in early 2023, marking a significant step towards safer opioid alternatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Ensysce Biosciences has initiated the PF614-104 trial, a study to evaluate the oral abuse potential of its drug PF614 compared to oxycodone. Conducted by Dr. Brad Vince, this randomized trial aims to demonstrate that PF614 has less drug liking potential, crucial for its abuse deterrent labeling. This follows the company's previous Human Abuse Potential study, reflecting significant progress in PF614's development. With PF614 exhibiting bioequivalence to OxyContin and a longer half-life for sustained pain relief, results are expected in early 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Ensysce Biosciences (NASDAQ:ENSC) announced its participation in the Benzinga All Access investor event on September 23, 2022. Dr. Lynn Kirkpatrick, CEO, will present at 9:20 AM Eastern time, followed by a Q&A session. The event will be available via a live video webcast, with an archived replay on the Benzinga YouTube Channel. Ensysce focuses on developing tamper-proof prescription drugs to enhance drug safety and combat abuse and overdose risks, leveraging its TAAP™ and MPAR™ technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Ensysce Biosciences held a special meeting of stockholders on September 8, 2022, where key resolutions were approved. Stockholders voted in favor of:

  • Issuing shares of common stock to certain investors, ensuring compliance with Nasdaq Listing Rule 5635(d).
  • Implementing a Reverse Stock Split at a ratio between one-for-five and one-for-twenty.
  • Increasing the number of authorized shares of common stock.

The decisions aim to strengthen the company’s capital structure and support ongoing clinical development initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Ensysce Biosciences has launched a redesigned corporate website highlighting its innovative TAAP and MPAR technology platforms aimed at improving prescription drug safety. The website aims to enhance communication about its unique, tamper-proof pain treatment options and the company's mission to combat drug abuse and overdoses. CEO Dr. Lynn Kirkpatrick emphasized the importance of showcasing their transformative chemistry as they progress towards commercialization. The redesign was executed by London-based Flipside Health, specializing in digital healthcare solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Ensysce Biosciences (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech firm, announced its participation in several upcoming conferences aimed at improving prescription drug safety. Key events include the PAINWeek Conference from September 6-9, 2022, where CEO Dr. Lynn Kirkpatrick will chair a symposium, and the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The meetings will provide opportunities for one-on-one discussions with company executives regarding their transformative technologies for pain management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What is the current stock price of Ensysce Biosciences (enscw)?

The current stock price of Ensysce Biosciences (enscw) is $0.021 as of July 3, 2025.
Ensysce Biosciences Inc

Nasdaq:ENSCW

ENSCW Rankings

ENSCW Stock Data

896.49k
Biotechnology
Healthcare
Link
United States
La Jolla